Atypical antipsychotic drugs and tardive dyskinesia: Relevance of D 2 receptor affinity

Journal of Psychopharmacology

Volumn 18, Issue 1, 2004, Pages 124-127

  Bressan, Rodrigo A ^a,b   Jones, Hugh M ^a   Pilowsky, Lyn S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antipsychotic agents; Atypical antipsychotic drugs; Clozapine; D 2 receptors; Dopamine; Olanzapine; Quetiapine; Risperidone; Tardive dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; ESTROGEN; LEVODOPA; OLANZAPINE; PHENYTOIN; QUETIAPINE;

ADULT; AKATHISIA; ARTICLE; BINDING AFFINITY; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC ACTIVITY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; RELAPSE; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 2442498598     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881104040251     Document Type: Article

References (29)

1. Alcohol Drug Abuse and Mental Health Administration (1974) Abnonnal involuntary movement scale (AIMS). Department of Health, Education and Welfare, Washington, DC
2. Almeida O P (1998) Olanzapine for the treatment of tardive dyskinesia. J Clin Psychiatry 59: 380-381
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn (DSM VI). American Psychiatric Press, Washington, DC
4. Ananth, J, Kenan, J (1999) Tardive dyskinesia associated with olanzapine monotherapy. J Clin Psychiatry 60: 870
5. Barnes T R (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676
6. Casey D E (1995) Tardive dyskinesia. In Borroni E, Kupfer D J (eds), Psychopharmacology: the fourth generation of progress, pp. 1497-1501. Raven Press Ltd, New York
7. Casey D E (1999) Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 35 (Suppl): S61-S66
8. Casey D E, Denney D (1977) Pharmacological characterization of tardive dyskinesia. Psychopharmacology (Berl) 54: 1-8
9. Gardos G, Cole J O (1995) The treatment of tardive dyskinesias. In Borroni E, Kupfer D J (eds), Psychopharmacology: the fourth generation of progress, pp. 1503-1511. Raven Press Ltd, New York
10. Glazer W M, Morgenstern H, Doucette J T (1993) Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 54: 133-139
11. Jones H M, Travis M J, Mulligan R, Bressan R A, Visvikis D, Gacinovic S, Eu P J, Pilowsky L S (2001) In vivo 5-HT2 A receptor blockade by quetiapine: an R91150 single photon emission tomography study. Psychopharmacology (Berl) 157: 60-66
12. Kane J M (1995) Tardive dyskinesia: epidemiological and clinical presentation. In Borroni E, Kupfer D J (eds), Psychopharmacology: the fourth generation of progress, pp. 1485-1495. Raven Press Ltd, New York
13. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158: 360-369
14. Kapur S, Zipursky R B, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293
15. Kapur S, Zipursky R, Jones C, Shammi C S, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57: 553-559
16. Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R (2001) Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 158: 311-314
17. Lieberman J A, Saltz B L, Johns C A, Pollack S, Borenstein M, Kane J (1991) The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158: 503-510
18. Llorca P M, Chereau I, Bayle F J, Lancon C (2002) Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 17: 129-138
19. Pilowsky L S, Mulligan R S, Acton P D, Ell P J, Costa D C, Kerwin R W (1997) Limbic selectivity of clozapine. Lancet 350: 490-491
20. Raja M, Azzoni A, Maisto G (1999) Three cases of improvement of tardive dyskinesia following olanzapine treatment. Int J Neuropsychopharmcol. 2: 333-334
21. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68: 29-39
22. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47: 27-38
23. Simpson G M, Angus J W (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212: 11-19
24. 123)I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 177: 408-415
25. Suzuki E, Obata M, Yoshida Y, Miyaoka H (2002) Tardive dyskinesia with risperidone and anticholinergics. Am J Psychiatry 159: 1948
26. Tollefson G D, Beasley C M Jr, Tamura R N, Tran P V, Potvin J H (1997) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154: 1248-1254
27. Travis M J, Busatto G F, Pilowsky L S, Mulligan R, Acton P D, Gacinovic S, Mertens J, Terriere D, Costa D C, Eu P J, Kerwin R W (1998) 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br J Psychiatry 173: 236-241
28. Vesely C, Kufferle B, Brucke T, Kasper S (2000) Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol 15: 57-60
29. Waddington J L (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl) 101: 431-447